Opinion|Videos|March 1, 2024
Updates from HER2CLIMB in HER2+ Metastatic Breast Cancer
Author(s)Carey K. Anders, MD
An expert on metastatic breast cancer provides clinical insights gleaned from the HER2CLIMB-02 trial and discusses the design and rationale of the ongoing HER2CLIMB-05 study.
Advertisement
Episodes in this series
Advertisement
Related to this article
In the phase 3 evERA trial, interim overall survival data showed a positive trend in favor of giredestrant/everolimus vs endocrine therapy plus everolimus.
10-year CHN HYPOPMRT data show 3-week postmastectomy RT with nodal irradiation maintains locoregional control without added severe late toxicity.
Advertisement
Advertisement
Trending on CancerNetwork
1
Prioritizing Proton Therapy for Pelvic Nodal Irradiation in Prostate Cancer
2
How Well Does Radiotherapy Pair With Dual PD-1/LAG-3 Blockade in NSCLC?
3
FDA OKs Pirtobrutinib in Frontline CLL/SLL
4
How Is Subcutaneous Administration Changing Oncology Care Delivery?
5